Altmetric

Genetically determined FXI (Factor XI) levels and risk of stroke

File Description SizeFormat 
Figure 1.tifSupporting information134.34 kBTIFFView/Open
Figure 2.tifSupporting information157.78 kBTIFFView/Open
Manuscript.docAccepted version428.5 kBMicrosoft WordView/Open
Supplement.pdfSupporting information997.78 kBAdobe PDFView/Open
Title: Genetically determined FXI (Factor XI) levels and risk of stroke
Authors: Gill, D
Georgakis, MK
Laffan, M
Sabater-Lleal, M
Malik, R
Tzoulaki, I
Veltkamp, R
Dehghan, A
Item Type: Journal Article
Abstract: Background and Purpose— FXI (factor XI) is involved in thrombus propagation and stabilization. It is unknown whether lower FXI levels have a protective effect on risk of ischemic stroke (IS) or myocardial infarction. This study investigated the effect of genetically determined FXI levels on risk of IS, myocardial infarction, and intracerebral hemorrhage. Methods— Two-sample Mendelian randomization analysis was performed. Instruments and genetic association estimates for FXI levels were obtained from a genome-wide association study of 16 169 individuals. Genetic association estimates for IS and its etiological subtypes were obtained from a study of 16 851 cases and 32 473 controls. For myocardial infarction, estimates were obtained from a study of 43 676 cases and 123 504 controls and for intracerebral hemorrhage from a study of 1545 cases and 1481 controls. Results— After applying a Bonferroni correction for multiple testing, the Mendelian randomization analysis supported a causal effect of higher, genetically determined FXI levels on risk of any IS (odds ratio [OR] per 1-unit increase in natural logarithm-transformed FXI levels, 2.54; 95% CI, 1.68–3.84; P=1×10−5) but not myocardial infarction (OR, 1.01; 95% CI, 0.76–1.34; P=0.94) or intracerebral hemorrhage (OR, 1.81; 95% CI, 0.44–7.38; P=0.41). Examining IS subtypes, the main results supported an effect of higher, genetically determined FXI levels on risk of cardioembolism (OR, 4.23; 95% CI, 1.94–9.19; P=3×10−4) and IS of undetermined cause (OR, 3.44; 95% CI, 1.79–6.60; P=2×10−4) but not large artery atherosclerosis (OR, 2.73; 95% CI, 1.15–6.45; P=0.02) or small artery occlusion (OR, 1.19; 95% CI, 0.50–2.82; P=0.69). However, the statistically significant result for IS of undetermined cause was not replicated in all sensitivity analyses. Conclusions— We find Mendelian randomization evidence supporting FXI as a possible target to reduce risk of the cardioembolic subtype of IS.
Issue Date: 1-Nov-2018
Date of Acceptance: 22-Aug-2018
URI: http://hdl.handle.net/10044/1/64302
DOI: https://dx.doi.org/10.1161/STROKEAHA.118.022792
ISSN: 0039-2499
Publisher: American Heart Association
Start Page: 2761
End Page: 2763
Journal / Book Title: Stroke
Volume: 49
Issue: 11
Copyright Statement: © 2018 American Heart Association, Inc.
Keywords: Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Peripheral Vascular Disease
Neurosciences & Neurology
Cardiovascular System & Cardiology
cardiovascular diseases
risk
stroke
MENDELIAN RANDOMIZATION
1103 Clinical Sciences
1102 Cardiovascular Medicine And Haematology
1109 Neurosciences
Neurology & Neurosurgery
Publication Status: Published
Online Publication Date: 2018-09-20
Appears in Collections:Department of Medicine
Faculty of Medicine
Epidemiology, Public Health and Primary Care



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx